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ABSTRACT
We present a bibliometric analysis of recently published full economic evaluations of health interventions and reﬂect critically
on the implications of our ﬁndings for this growing ﬁeld. We created a database drawing on 14 health, economic, and/or
general literature databases for articles published between 1 January 2012 and 3 May 2014 and identiﬁed 2844 economic
evaluations meeting our criteria. We present ﬁndings regarding the sensitivity, speciﬁcity, and added value of searches in
the different databases. We examine the distribution of publications between countries, regions, and health areas studied
and compare the relative volume of research with disease burden. We analyse authors’ country and institutional afﬁliations,
journals and journal type, language, and type of economic evaluation conducted. More than 1200 economic evaluations were
published annually, of which 4% addressed low-income countries, 4% lower-middle-income countries, 14% upper-middle-
income countries, and 83% high-income countries. Across country income levels, 53, 54, 86, and 100% of articles, respec-
tively, included an author based in a country within the income level studied. Biomedical journals published 74% of economic
evaluations. The volume of research across health areas correlates more closely with disease burden in high-income than in
low-income and middle-income countries. Our ﬁndings provide an empirical basis for further study on methods, research
prioritization, and capacity development in health economic evaluation.
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1. INTRODUCTION
In 2012, Wagstaff and Culyer published a high-proﬁle bibliometric analysis that set out to characterise the
entirety of the health economics ﬁeld, updating and extending prior work by Rubin and Chang (2003). Their
ambitious work examined publications across 42 years (1969–2010) and generated much discussed rankings
of the leading authors, institutions, and topics of health economics research over time. By restricting their
analyses to journals indexed in EconLit, however, they omitted the substantial body of health economics
research published in the medical literature, including many economic evaluations of health interventions. This
important and growing area of health economics examines the relative efﬁciency of alternative courses of
action in improving health (Drummond et al., 2005).
To address this gap, we present a bibliometric analysis of recently published, full health economic evalua-
tions (Drummond et al., 2005) and reﬂect critically on the implications of our ﬁndings. Bibliometric analysis is
deﬁned as the quantitative study of written communication in forms such as journal articles and books
(Pritchard, 1969). It sets out to characterise a literature, rather than examine the ﬁndings of that literature, which
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is the approach of a systematic review. We stratify our analyses of the economic evaluation literature by the
income group classiﬁcation of the countries studied (World Bank, 2015). This stratiﬁcation ensures that
ﬁndings regarding low-income and middle-income countries (LMICs) receive due attention, given that they
are home to 84% of the world’s population and bear 89% of the global burden of disease (GBD) (World Health
Organization (WHO), 2014). In light of the growing interest in global health and priority setting, this contribu-
tion to the evidence base is also timely.
A previous bibliometric analysis of cost-effectiveness analyses (CEAs) was limited to studies reporting
outcomes as cost per quality-adjusted life-year (QALY) up to 2006 published in English in journals indexed
in Medline (Greenberg et al., 2010). As QALYs were infrequently used in LMICs up to 2006, this restriction
biased Greenberg et al.’s ﬁndings towards studies undertaken in HICs and omitted nearly half of full economic
evaluations (as we will show). Much has also changed since 2006, with a rapid expansion in the literature, in-
cluding in LMICs.
By 1984, just a handful of economic evaluations of health interventions had been conducted in LMICs
(Mills and Thomas, 1984) and even in 2000, Walker and Fox-Rushby (2000) were still able to review critically
the 107 economic evaluations of interventions to address communicable diseases in LMICs published between
1984 and 1997. In the past decade, however, the body of work has expanded such that it has been possible for
reviews to focus on speciﬁc disease areas, for example non-communicable diseases (Mulligan et al., 2006);
road trafﬁc injuries (Waters et al., 2004); malaria (Goodman and Mills, 1999, White et al., 2011); various as-
pects of HIV/AIDS (Creese et al., 2002, Galarraga et al., 2009, Walensky et al., 2010, Johri and Ako-Arrey,
2011) and tuberculosis (Fitzpatrick and Floyd, 2012, Chavan et al., 2011); vaccination for Haemophilus
inﬂuenzae type b (Grifﬁths and Miners, 2009), seasonal (Ott et al., 2013) and pandemic inﬂuenza (Perez
Velasco et al., 2012); human papilloma virus (Natunen et al., 2013, Fesenfeld et al., 2013); cardiovascular dis-
eases (Suhrcke et al., 2012); surgery (Chao et al., 2014); and strategies to improve the demand and supply of
maternal and neonatal care (Mangham-Jefferies et al., 2014). Reviews of economic evaluations in LMICs have
also narrowed their focus by geography, for example to Meso-America (Valencia-Mendoza et al., 2011), Latin
America and the Caribbean (Augustovski et al., 2009), Thailand (Teerawattananon et al., 2007), Nigeria
(Gavaza et al., 2010), Tanzania (Mori and Robberstad, 2012), and Ghana (Odame, 2013). In adopting a more
constrained perspective, these reviews have allowed important insights into the economic evidence for speciﬁc
disease areas or geographies, but have not provided a wider perspective on the overall economic evaluation lit-
erature in LMICs, nor been able to compare this literature with the far larger body of economic evaluations in
high-income countries (HICs).
We aim to provide a recent snapshot of the state of the economic evaluation ﬁeld. In the following sections,
we describe the methods for generating and analysing our data, present our results, and reﬂect on the state of the
ﬁeld and the implications of our ﬁndings for research priority setting and capacity development.
2. METHODS
We began by developing a comprehensive database of peer-reviewed research articles reporting a primary, full
economic evaluation. Following Drummond et al. (2008), we deﬁned ‘full economic evaluation’ as studies
which evaluate the efﬁciency of alternative interventions or courses of action by combining data on the costs
and effects on human health of the alternatives in CEA, cost-utility analysis (CUA), or cost-beneﬁt analysis
(CBA). Further, we aimed to restrict our database to articles which went beyond simple reporting of some cost
and effect data, and instead included only articles which either (i) produced a summary measure of efﬁciency,
such as a ratio (e.g. incremental cost-effectiveness ratio), probability (e.g. that an intervention is cost-effective
given a deﬁned threshold), difference (e.g. incremental net beneﬁt), and/or graph, such as a cost-effectiveness
plane or cost-effectiveness acceptability curve as recommended in International Society for Pharmacoeconomics
and Outcomes Research guidelines (Ramsey et al., 2005), or (ii) which demonstrated strict dominance (i.e. that
one intervention is both more costly and less effective than the other). We deﬁned ‘primary research’ to include
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the production of a novel estimate (i.e. to include modelling studies) and to exclude reviews which only cite pre-
viously published estimates.
Our analysis was restricted to articles published from 1 January 2012 to the date of our searches, 3 May
2014, comprising a period of 28 months. This restriction reﬂects both our aim to provide a recent snapshot
of a rapidly changing ﬁeld and also practical considerations, since even this restricted timeframe required
screening, cleaning, and coding large volumes of data. In the following sections we describe the process of con-
structing the database and our analytical methods.
2.1. Data
Search strategies. Figure S1 illustrates our search strategy in a ﬂow diagram adapted from the PRISMA
guidelines for systematic reviews.(Liberati et al., 2009) We identiﬁed 17 potential databases for our search
by consulting recent systematic reviews of economic evaluations and a health sciences librarian to identify
databases which seemed, prima facie, to be potentially useful or used by researchers.
Based on preliminary searches in all databases and a review of their content and functionality, we selected
14 databases for our ﬁnal search: two health economics databases (the National Health Service Economic
Evaluations Database (NHS EED) and the Health Economic Evaluations Database (HEED)), one economics
database (EconLit), one general literature database (Scopus), two broad databases (the Science Citation Index
Extended (SCI), and the Social Science Citation Index, which were searched simultaneously), and eight health
sciences databases (Embase, Medline including in-process, Latin American Health Sciences Literature
(LILACS), Global Health, PsycInfo, Scielo, Biosis, and Cinahl). We excluded Google Scholar because Google
prohibits bulk downloading of citations; Pubmed because we were able to obtain the same set of articles
(Medline, Medline-in-process, and Pubmed-not-Medline) in our search using the Ovid SP interface, which
we also used to access EconLit, Embase, Global Health, and PsycInfo, and the Tufts Cost-Effectiveness
Analysis Registry because its coverage was limited to articles published in English which report outcomes
as QALYs and it charges substantial access fees.
Search strategies were optimised individually for each database, taking into account the scope of each
database and the features of its user interface. Careful checks were performed to ensure that the initial search
was as sensitive as possible and that any restrictions increased speciﬁcity without compromising sensitivity.
Each time we considered an additional restriction to increase the speciﬁcity of the search, such as excluding
all articles with the word ‘protocol’ in the title, we ﬁrst reviewed the ﬁrst 100 excluded records, and revised
the search strategy if any excluded records were found to meet our inclusion criteria. Full details of the ﬁnal
search strategy employed in each database are provided in Table S1 and further discussion of the reasons for
not using controlled vocabulary indexing terms (e.g. MeSH terms) is available in Text S1.
Merging and screening. Search results were exported to Excel. We identiﬁed duplicate records to produce a set
of unique records linked to the bibliographic data in all of the databases in which they were found. By
comparing multiple databases and carefully reviewing data, we corrected many of the errors within the biblio-
graphic data. Titles and, if necessary, abstracts and in some cases full text were screened by one author (CP) to
determine whether they met our inclusion criteria. Although only English-language search terms were used, no
language restrictions were applied. Keyword searches of all text ﬁelds were used to facilitate identiﬁcation of
articles for exclusion (using terms such as ‘review’ and ‘protocol’) and inclusion (using terms such as ‘domi-
nant’ and ‘cost-utility’).
We excluded articles which described themselves as CEA, CUA, or CBA but did not meet our inclusion
criteria. For example, self-proclaimed ‘cost-beneﬁt analyses’ which only compared the costs of interventions
with cost savings resulting from reduced subsequent health care use were excluded as they did not measure
health beneﬁts. Cost-minimization analyses were similarly excluded (Dakin and Wordsworth, 2013), as were
the many articles declaring an intervention ‘cost-effective’ which did not analyse both costs and effects.
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2.2. Analyses
All analyses are disaggregated by country income group and were conducted in Microsoft Excel.
Databases. For each of the 14 databases, we provide estimates of the sensitivity1 and speciﬁcity2 of our
search. Given the substantial overlap between databases and to allow us to identify the minimum number
of databases required to achieve a given overall sensitivity, we also assessed the added value of each
database ﬁrstly, by identifying the database yielding the greatest number of economic evaluations, and
secondly, by ranking the remaining databases in descending order according to the number of additional
economic evaluations they identiﬁed beyond those already identiﬁed by a more highly ranked database.
Geographical areas studied. Key term searches were developed to classify articles by country (or countries)
studied, which were then mapped onto World Bank income groups and regions (World Bank, 2015).3 All
potentially ambiguous country names were reviewed,4 as were all articles not classiﬁed by any search term
or classiﬁed as analysing multiple income groups. Articles which described themselves as studying a region
or set of countries (such as ‘malaria endemic countries’ (WHO Global Malaria Programme, 2014)) were
classiﬁed according to all the countries within that region. A single article could be classiﬁed as belonging
to multiple income levels or regions.
Health areas. We developed a classiﬁcation of 25 health areas so as to allow comparability with the global
burden of disease (GBD) estimates (WHO, 2014), to be implementable with an electronic key term search,
and to permit meaningful analysis. In Table S2, we show how our 25 health areas map onto the GBD and onto
the WHO’s International Classiﬁcation of Disease, version 10 (WHO, 2011). A set of up to 49 search terms was
developed for each of our health areas through an iterative process.
As with countries studied, a single article could be classiﬁed as belonging to multiple health areas. For
example, we counted economic evaluations of interventions for gestational diabetes as both ‘maternal and
newborn health’ and ‘diabetes’, and interventions to address HIV and tuberculosis co-infection (Pawlowski
et al., 2012) as addressing each disease. While this could be considered double-counting, we argue that
interventions addressing multiple areas do not contribute any less to each area than those interventions address-
ing only one disease. Further information is available in Text S2.
We then compared the distribution of health areas studied in economic evaluations to the GBD. Comparisons
are presented graphically with scatter plots comparing the volume of economic evaluations and burden of dis-
ease by (i) ranking and (ii) proportion of total, disaggregated by income group and in total, which allows us both
to assess the correlation and to identify health areas which are outliers meriting deeper exploration.
Languages and journals. Journals were classiﬁed as follows: (i) biomedical; (ii) health economics, services,
policy, and/or social sciences; or (iii) other (Table S3). We analysed the proportion of health economic
evaluations published in each journal type, the top 20 journals, and the concentration of economic evaluations
by income group and in total.
The language of the full text was also analysed. Where the full text was available in English and another
language, the article was categorised as English to permit analysis of what would be missed if only
1Sensitivity = (number of economic evaluations identiﬁed by our search of the given database) / (total number of economic evaluations
identiﬁed in our ﬁnal economic evaluation database).
2Speciﬁcity = (number of economic evaluations identiﬁed by our search of the given database) / (total number of records identiﬁed by our
search of the given database).
3Macao, Hong Kong, and Taiwan, which are all classiﬁed as high-income countries by the World Bank, were analysed separately from the
mainland of the People’s Republic of China, an upper-middle-income country.
4Potentially ambiguous country names included for example, ‘Congo’, ‘Korea’, ‘Niger’, and ‘Guinea’, each of which is contained within
more than one country name; ‘China’, which is often used in reference to Taiwan, Hong Kong, and Macao; ‘Japan’, which appears within
the bibliographic data of studies of Japanese encephalitis; and ‘England’, which may refer to the United Kingdom, to New England in the
USA, or to studies published in the New England Journal of Medicine.
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English-language publications were considered. As there were many errors in the language data in the biblio-
graphic databases, these data were also compared with the journal name and country studied, and in some cases
the full text or journal website examined, to arrive at a ﬁnal language classiﬁcation.
Types of economic evaluation.We used key term searches to disaggregate studies by self-reported type: CBA,
CUA, and other CEAs. We further disaggregated cost-utility studies between those employing disability-
adjusted life-years (DALYs) and those employing QALYs. Search terms are listed in Table S4.
Institutional and geographical afﬁliations of authors. We analysed data on the institutional afﬁliation of all
authors to develop a comprehensive picture of the institutions and countries contributing to health economic
evaluations.
We identiﬁed the top 10 institutions within each income group by volume of economic evaluations produced.
As in previous work (Wagstaff and Culyer, 2012, Rubin and Chang, 2003), schools, colleges, and institutes were
aggregated with the university to which they belonged, with the exception of the highly federal Universities of
London, California, Texas, and other similar university systems, whose constituent members were analysed
separately.
We considered a number of possible approaches for analysing articles with more than one institutional
afﬁliation, including assigning a fractional value (and even weighted fractional values reﬂecting author order)
to each institution based on the number of authors or institutions represented on a given article (Aksnes et al.,
2012, Hagen, 2013, Retzer and Jurasinski, 2009). However, we rejected such approaches because using zero-
sum metrics, in general, establishes a perverse incentive against collaboration between institutions and against
the crediting of collaborators. We therefore assigned one point per institution per article, regardless of the
number of institutions or authors on a given article. This has the disadvantage of weighting the analysis towards
articles from multiple institutions, as these articles are counted multiple times in the analyses of institutional and
country afﬁliations. More information on how we classiﬁed health areas and institutional afﬁliations is available
in Text S2.
3. RESULTS
3.1. Search results
In total, our searches of the 14 databases identiﬁed 47 407 records (Figure S1). After duplicate removal, 15 057
unique records remained, and after screening, a total of 2844 unique, full economic evaluations were retained for
analysis.
3.2. Databases
Our search of Scopus identiﬁed the largest number of economic evaluations (n=2409), 85% of our total, followed
by NHS EED, which identiﬁed 80% of the articles we identiﬁed (Table S5). Together, these two databases iden-
tiﬁed 96% of articles, and adding the Medline search increased this to 98%. With each additional database, the
incremental gains were diminishingly small, and one database, Lilacs, failed to identify any additional articles be-
yond those identiﬁed by other databases. Econlit identiﬁed just 42 economic evaluations, 1% of the total. If we
exclude NHS EED from consideration as it ceased to update records fromMarch 2015 and exclude Wiley HEED
as it ceased to be available from the end of 2014, our searches of a combination of Scopus, Medline, and Global
Health would identify 91% of the economic evaluations, but a remaining 7% of economic evaluations in our da-
tabase were only identiﬁed by NHS EED andWiley HEED and not by our searches of other databases (Table S6).
If we restrict the analysis to articles studying LMICs and exclude NHS EED and Wiley HEED, our searches of
Scopus, Medline, and Global Health would together identify 93% of economic evaluations in LMIC settings,
while 4% were only identiﬁed in NHS EED and Wiley HEED (Table S7).
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3.3. Subjects studied
Geographical areas studied. At least one country, region, and income group studied was assigned to all
economic evaluations identiﬁed. Of these, 83% studied HICs, 14% upper-MICs, 4% lower-MICs and 4% LICs.
These sum to more than 100% because 2% of articles reported studies set in multiple countries in more than one
of the four income groups. As expected, most articles reported ﬁndings from Europe and Central Asia (44%)
and/or North America (34%) (Table I).
Table II and Figure 1 present the individual countries most frequently studied. The United States (USA) was
the subject of 813 studies, followed by the United Kingdom (UK) (n=478) and six further countries which were
each studied in at least 100 articles. While China, South Africa, and Brazil were studied in a relatively large num-
ber of articles, only 10 upper-MICs were studied in at least 20 articles each. Led by Uganda, India, Kenya, and
Zambia, all of the top 20 LICs and lower-MICs were studied in more than 20 economic evaluations, in part
because 61 of the 184 articles (33%) studying at least one LIC or lower MIC examined more than one country
Table I. Number of economic evaluations by income group and region of study
Income group(s) of countries studied
Region(s) studied Low Lower-middle Upper-middle High Multiplea Total % of total
East Asia and Paciﬁc 22 43 165 229 25 405 14%
Europe and Central Asia 11 16 44 1210 20 1243 44%
Latin America and Caribbean 13 18 116 16 19 129 5%
Middle East and North Africa 14 20 43 27 20 62 2%
North America 1 1 1 960 1 960 34%
South Asia 27 49 20 15 25 56 2%
Sub-Saharan Africa 92 64 78 22 46 158 6%
Multiplea 27 35 31 85 38 102 4%
Total 104 121 391 2350 63 2844 100%
% of total 4% 4% 14% 83% 2% 100%
aArticles studying at least two countries of differing income levels or regions are categorised as ‘Multiple’.
Table II. Top 20 countries most frequently studied in economic evaluations by income group
High income Upper-middle-income Low and lower-middle-income
Rank Country N % Country N % Country N %
1 USA 813 35% China 116 30% Uganda 49 27%
2 UK 478 20% South Africa 71 18% Indiaa 41 22%
3 Netherlands 183 8% Brazil 56 14% Kenyaa 41 22%
4 Canada 162 7% Thailand 36 9% Zambia 39 21%
5 Spain 136 6% Iran 31 8% Malawi 35 19%
6 Germany 109 5% Colombiaa 28 7% Nigeriaa 34 18%
7 Australia 100 4% Mexicoa 28 7% Tanzaniaa 34 18%
8 Italy 98 4% Turkey 24 6% Zimbabwe 33 18%
9 Sweden 74 3% Botswanaa 23 6% Congo, Dem. Rep. 30 16%
10 France 57 2% Namibiaa 23 6% Ethiopia 29 16%
11 Japan 45 2% Angola 18 5% Lesothoa 28 15%
12 Belgium 42 2% Gabon 17 4% Mozambiquea 28 15%
13 Denmark 33 2% Mauritiusa 14 4% Rwandaa 28 15%
14 Korea, Rep.a 31 1% Perua 14 4% Vietnama 28 15%
15 Norwaya 31 1% Seychellesa 14 4% Ghana 27 15%
16 Greece 29 1% Bulgaria 13 3% Central African Republic 26 14%
17 Ireland 27 1% Argentinaa 12 3% Burundia 25 14%
18 Switzerlanda 24 1% Hungarya 12 3% Cameroona 25 14%
19 Finlanda 24 1% Maldives 11 3% Eritreaa 25 14%
20 Taiwan 23 1% Serbia 10 3% Burkina Faso 24 13%
High-income
countries
2350 100% Upper-middle-income
countries
391 100% Low- and lower-middle-income
countries
184 100%
aEqual ranking with country above and/or below.
C. PITT ET AL.14
© 2016 The Authors. Health Economics published by John Wiley & Sons Ltd. Health Econ. 25(Suppl. 1): 9–28 (2016)
DOI: 10.1002/hec
and 33 LIC and lower MIC articles (18%) studied more than 10 countries. In upper-MICs and HICs, only 14%
(n=54) and 7% (n=169) of studies, respectively, examined more than one country and 8% (n=32) and 1%
(n=27) examined more than 10 countries.
Health areas studied and the global burden of disease. At least one health area was assigned to 2829 (99.5%)
articles. The mean number of health areas per article was 1.4 and the maximum 7. Whereas 71% of articles
were assigned a single health area, 21% addressed two health areas and 8% addressed three or more. In LICs,
three health areas dominate: HIV/AIDS (30% of classiﬁed LIC articles), neonatal and maternal conditions
(16%), and malaria (15%) (Table III). In lower-MICs, HIV/AIDS again dominates (23%), but the remaining
health areas are more evenly distributed; malaria comes second (11%), and is followed by other infectious
diseases (8%) and mental health (8%); half of the latter focused on HIV treatment and prevention amongst
injection drug users. In upper-MICs, HIV/AIDS (12%) falls to second place, while cancer and other neoplasms
(19%) occupy the top spot with cardiovascular (11%) and respiratory diseases (10%) in third and fourth respec-
tively. As HICs are studied in 83% of economic evaluations, the disease areas addressed in economic evalua-
tions in HICs drive the distribution of all economic evaluations conducted worldwide, with cardiovascular
diseases (19% in HICs), cancer and other neoplasms (18%), mental health (10%), and musculoskeletal diseases
(10%), the leading areas of study in HICs and overall (Table III).
The distribution of articles across health areas corresponds substantially but by no means perfectly
with the global disease burden. The degree of correlation varies by income level, but also depends on
whether rankings or proportions are compared. By either metric, the health areas studied in HICs
correlate surprisingly well with disease burden and substantially better than economic evaluations in other
income groups, which feature more numerous and extreme outliers (Figure 2). The correlation between
the health focus of economic evaluations and disease burden is also substantially stronger in studies of
HICs than globally, because most economic evaluations (83%) address HICs and are well correlated with
HICs’ disease burden, whereas most of the GBD (89%) affects LMICs.
HIV/AIDS is studied in a greater proportion of economic evaluations at every income level than its share of
the disease burden; however, the gap is much smaller in HICs than in LICs and lower-MICs, where it is an
Figure 1. Number of economic evaluations set in each country. The intensity of shading reﬂects the number of economic evaluations
analyzing each country over the 28-month period from 1 January 2012 to 3 May 2014
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extreme outlier. Other such ‘winners’ across all income levels include ‘other infectious diseases’; ‘genitouri-
nary diseases, contraception, and fertility’; and ‘sexually transmitted diseases (excluding HIV)’. By contrast,
interventions to address wounds and injuries and, to a somewhat lesser extent, neurological conditions, appear
to be substantially under-researched relative to disease burden at every income level.
Figure 2. Economic evaluations versus burden of disease by income group. Results are presented in two ways: the lefthand column com-
pares the proportion of the total number of economic evaluations examining each of the 25 health area with the proportion of the total bur-
den of disease accounted for by each health area and the righthand column compares the ranking of the health areas by the volume of
economic evaluations and by burden of disease
C. PITT ET AL.16
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3.4. Journals and languages
Economic evaluations were published in a total of 967 different journals (Table S8). Five hundred ﬁfty-nine
journals published only one economic evaluation each in the entire 28-month period we analysed and 165
journals published only two. Whereas 802 different journals published HIC articles, only 44 published
LIC articles. The proportion of articles published in the top 20 journals for each income group increased
Table III. Number of economic evaluations by health area and income group
Income group studied
Health area Low Lower-middle Upper-middle High World
Cancer and other neoplasms 7 8 73 416 492
Cardiovascular diseases 3 7 44 448 490
Mental health, cognition, and developmental and behavioural disorders
(including self-harm and substance disorders)
1 10 21 243 268
Musculoskeletal diseases (including back pain) 2 3 18 240 262
Respiratory diseases 6 8 39 188 228
Genitourinary diseases, contraception & fertility 4 4 18 180 203
Other infectious diseases (including encephalitis, hepatitis, other
parasitic and vector-borne diseases, and nematode infections)
6 10 38 111 159
Digestive disorders 3 3 21 127 152
Neonatal and maternal conditions 17 7 23 102 142
HIV/AIDS 31 27 46 61 136
Diabetes 1 3 22 102 125
Malnutrition (including obesity and exercise) 6 4 9 98 113
Wounds and injuries (including violence) 4 7 13 91 109
Endocrine, blood, and immune disorders (excluding diabetes or HIV) 0 1 12 86 99
Neurological conditions 1 3 16 81 98
Skin and oral conditions 0 3 5 67 75
Sense organ diseases 2 3 11 56 68
Tuberculosis 8 9 28 34 62
Sexually transmitted diseases (excluding HIV) 2 1 10 39 49
Diarrhoeal diseases 6 7 9 29 46
Communicable childhood diseases 2 5 9 24 40
Malaria 16 13 8 1 24
Congenital anomalies 0 1 2 20 23
Anaemia 0 1 1 9 11
Meningitis 2 2 3 3 9
TOTAL 104 120 390 2337 2829
A single economic evaluation may address more than one health area in countries of more than one income group. The totals exclude the 15
articles (0.5%) in our data set which could not be classiﬁed by health area.
Figure 3. Proportion of economic evaluations by journal type and income group. The classiﬁcation of journals by type is provided in Web
appendix 6. Articles are disaggregated by the income group(s) of the country or countries studied
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steeply down the income groups: 29% of articles studying HICs were published in the top 20 journals
publishing HIC evaluations, while 38, 66, and 77% of articles studying upper-MICs, lower-MICs, and LICs,
respectively, were published in the top 20 journals publishing evaluations set in each of the respective
income groups.
Overall, 74% of articles were published in biomedical rather than health economics, systems, and policy
journals (22%) or other journal types (5%) (Figure 3). In HICs, 6 of the top 10 journals were health economics,
systems, or policy journals, compared with only 3 of the top 10 journals publishing articles about LICs and
lower-MICs (Table IV). The top outlet for economic evaluations across all income levels was PLoS ONE, an
open-access journal publishing ‘primary research from any scientiﬁc discipline’, which ranked amongst the
top three journals for all income groups. Vaccine ranked fourth overall (n=66) and in the top ﬁve for all income
groups. Yet overall, journals tended towards segregation by income group; 6 of the top 10 journals publishing
economic evaluations about HICs did not publish a single LIC or lower MIC study and two of the remaining
published only one each.
All articles addressing LICs and lower-MICs were published in English, while 4% of HIC articles (n=89)
were published in other languages, as was a striking 22% (n=87) of all articles addressing upper-MICs. In
upper-MICs, Chinese was the leading non-English language (n=48, 12%), followed by Spanish (23, 6%),
Portuguese (n=13, 3%), Turkish (n=2, 1%), and Farsi (n=1, 0%), while in HICs, Spanish was the language
of full-text for 46 articles (2%), followed by German (n=13, 1%), and 10 other languages.
3.5. Types of economic evaluation
Although the term is widely (mis)used in the literature, genuine cost-beneﬁt analyses are very rare; we
excluded many articles from our database which described themselves as CBAs of health interventions
but did not value health or welfare outcomes. Of the 147 (5%) articles in our database which described
themselves as CBAs, some do not in fact place a monetary value on health outcomes and should probably
be described as CEAs or CUAs; however, for consistency and feasibility, our analysis of evaluation type is
based on key term searches, and therefore reﬂect the authors’ classiﬁcation (Table S4). Cost-utility analyses
accounted for at least half of economic evaluations across all income levels, ranging from 50% (n=52) in
LICs to 62% (n=1448) in HICs. The proportion of CUAs employing DALYs decreases from 87%
(n=45) in LICs to 2% (n=35) in HICs, while the proportion employing QALYs increases from 13%
(n=7) in LICs to 35% (n=23) in lower-MICs, 68% (n=123) in upper-MICs, and 96% (n=1385) in HICs.
A very small proportion of studies described themselves as CUAs but did not contain any search terms for
DALYs or QALYs (Figure 4 and Table S9).
Figure 4. Proportion of economic evaluations by analytical type and income group studied. In this ﬁgure, ‘cost-effectiveness anal-
ysis’ refers to articles meeting our deﬁnition of a full economic evaluation but not containing any keywords to deﬁne it more
speciﬁcally as a cost-utility or cost-beneﬁt analysis. Articles can be classiﬁed as both cost-utility and cost-beneﬁt analyses if they
contain keywords for both. Articles are disaggregated by the income group(s) of the country or countries studied. CBA: cost-beneﬁt
analysis, CEA: cost-effectiveness analysis, CUA: cost-utility analysis, DALY: disability-adjusted life-year, QALY: quality-adjusted
life-year
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3.6. Authors’ geographical and institutional afﬁliations
Author afﬁliation data were obtained for all articles. At least one author was afﬁliated with an institution in the
USA or the UK on 1145 (40%) and 619 (22%) of articles respectively (Table V). China-based authors
Table V. Most frequent countries of institutional afﬁliation of authors
High-income Upper-middle-income Low-income and lower-middle-income
Rank Country N Country N Country N
1 USA 1145 China 116 India 22
2 UK 619 Brazil 51 Uganda 20
3 Netherlands 267 South Africa 49 Kenya 13
4 Canada 238 Thailand 37 Vietnam 11
5 Australia 191 Colombia 32 Ghanaa 9
6 Germany 151 Mexico 26 Zambiaa 9
7 Spain 147 Iran 25 Nigeria 8
8 Switzerland 104 Turkey 18 Indonesiaa 5
9 France 103 Argentina 14 Burkina Fasoa 5
10 Italy 99 Malaysia 12 Bangladesha 4
11 Sweden 98 Peru 9 Pakistana 4
12 Belgium 78 Bulgariaa 7 Tanzaniaa 4
13 Japan 53 Serbiaa 7 Philippinesa 4
14 Denmark 45 Hungary 5 Egypta 4
15 Ireland 39 Venezuela 3 Ethiopiaa 2
16 Norway 32 Romaniaa 2 Malawia 2
17 Taiwan 28 Lebanona 2 Congo, Dem. Rep.a 2
18 Finland 27 Costa Ricaa 2 Benina 2
19 Korea, Rep.a 25 Jordana 2 Myanmara 2
20 Austriaa 25 Tunisiaa 2 Zimbabwea 2
21 Greece 23 Iraqa 1 Cameroona 2
22 Hong Kong 21 Botswanaa 1 Senegala 2
23 Singapore 21 Cubaa 1 Sri Lankaa 1
24 New Zealanda 19 Kazakhstana 1 Cambodiaa 1
25 Polanda 19 Panamaa 1 Nigera 1
26 Portugal 15 Jamaicaa 1 Afghanistana 1
27 Israel 12 Dominican Republica 1 Nepala 1
28 Russia 9 Rwandaa 1
29 Chile 8 Sierra Leonea 1
30 Czech Republic 7 Somaliaa 1
31 Sloveniaa 5 Syriaa 1
32 Qatara 5 Boliviaa 1
33 Croatiaa 2 Guyanaa 1
34 Saudi Arabiaa 2 Uzbekistana 1
35 Estoniaa 2 West Bank and Gazaa 1
36 Icelanda, Liechtensteina, Lithuaniaa, Macaoa,
Maltaa, Puerto Ricoa, Trinidad and Tobagoa
1
The table ranks countries of institutional afﬁliations of authors by the number of economic evaluations including at least one author
afﬁliated with that country. All countries afﬁliated with at least one author of at least one economic evaluation are listed.
aEqual ranking with country above and/or below.
Table VI. Income group studied versus income group of author afﬁliations
Income group of authors’ country afﬁliation(s)
Income group of countries studied Low Lower-middle Upper-middle High Total
Low 55 (53%) 7 (7%) 16 (15%) 98 (94%) 104 (100%)
Lower-middle 8 (7%) 65 (54%) 15 (12%) 99 (82%) 121 (100%)
Upper-middle 11 (3%) 11 (3%) 338 (86%) 175 (45%) 391 (100%)
High 4 (0%) 12 (1%) 51 (2%) 2345 (100%) 2350 (100%)
Total 59 (2%) 80 (3%) 394 (14%) 2601 (91%) 2844 (100%)
Row percentages are presented and reﬂect the proportion of articles addressing a given income level, which include authors afﬁliated with
institutions based in a country of the given income level.
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contributed to 4% (n=116) of all articles, making it the ninth largest contributor to economic evaluations, while
Brazil (51, 2%) and South Africa (49, 2%) also ranked within the top 20 country afﬁliations. With 22 articles
(1%), India was the highest ranking lower MIC and ranked 29th overall, just ahead of Hong Kong and
Singapore. Uganda was the largest contributor to economic evaluations amongst LICs with 20 articles (1%)
and ranked 32nd overall just ahead of New Zealand. In general, the lists of leading country afﬁliations of authors
within each income group strongly resemble the leading countries studied. Even for Uganda, however, the largest
LIC contributor, 30 of the 49 articles about the country did not include any Uganda-based authors; of these, 25
were studies set in at least 15 countries each, but 5 articles focused on 3 or fewer countries.
On 91% of articles, at least one author was based in a HIC (Table VI). All but 5 of the 2350 articles studying
HICs included at least one author based in a HIC and most articles studying upper-MICs included at least one
upper MIC-based author (n=338, 86%). By contrast, only 53 and 54% of articles studying LICs and
lower-MICs, respectively, included any author based in an institution in the respective income group. Authors
based in upper-MICs contributed to a relatively small proportion of articles analyzing LICs (n=16, 15%) or
lower-MICs (n=15, 12%), and in nearly half of these articles, upper-MICs were also studied. Authors based
in HIC institutions contributed to 94% (n=98) of articles analyzing LICs and 82% (n=99) analyzing lower-
MICs, compared with fewer than half of evaluations in upper-MICs (n=175, 45%). Of the 65 articles studying
LIC and lower-MIC which did not include an author from those income levels, 44 articles included at least one
author based in the USA (68%). At least one author listed a major pharmaceutical company amongst the insti-
tutional afﬁliations on 9% of articles (n=246) overall, varying from 9% (n=221) of articles studying HICs, to
12% (n=46) studying an upper-MIC, 7% (n=8) studying a lower-MIC and 4% (n=4) studying a LIC. English
is an ofﬁcial language in four of the top ﬁve HICs and LICs and lower-MICs contributing to economic evalu-
ations, compared with just one of the top ﬁve upper-MICs (Table VII).
Harvard University, including its afﬁliated hospitals, was by some distance the institution contributing to the
largest number of economic evaluations (n=152). The top institutions producing economic evaluations in LICs
and lower-MICs are notable for their low individual and collective output, as well as for including many
ministries of health or (semi-)autonomous research institutes (Table VII). The leading LIC or lower MIC insti-
tution, Makerere University, was listed amongst the author afﬁliations of 14 economic evaluations over the
2.3 years we studied. The WHO was listed amongst the author afﬁliations on 25 articles, while the World Bank
and United Nations’ Children’s Fund contributed to only four economic evaluations each.
4. DISCUSSION
Our analysis provides an evidence base from which to discuss the current state of the economic evaluation ﬁeld
and has generated many questions which warrant further investigation. Some of these issues are examined in
other papers in this special issue. For example, Grifﬁths et al. (2016) compare the methods used in economic
evaluations in countries of differing income groups in a representative sample of articles from the database we
created, while other authors examine costing methods (Sweeney et al., 2016, Cunnama et al., 2016), outcome
metrics (Greco et al., 2016), and issues around capacity to produce and to use economic evaluations (Kaló
et al., 2016). Our analysis also offers insights to strengthen the process of prioritising, conducting, publishing,
and developing capacity for economic evaluation research. Here, we discuss the state of the ﬁeld and the im-
plications of our ﬁndings for research priority setting and capacity development.
4.1. The state of health economic evaluation
We identiﬁed a large volume of economic evaluations—2844 over 28 months—including 1273 in 2013 alone.
The principal economics database, EconLit, contains 5483 publications with ‘Health’ JEL codes for 2012 and
2013, but captured just 1% of economic evaluations published in those years. A large majority of economic
evaluations were published in biomedical journals and even many of the journals we categorised as ‘health eco-
nomics, services, and policy’ are not indexed in EconLit. Adding the 2413 economic evaluations we identiﬁed
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for 2012 and 2013 to the EconLit health records would increase the volume of ‘health economics’ research by
44%. Further, these publications still do not include the many other health economic analyses of, for example
equity, demand, markets, and incentives, which are published in journals outside the economics literature as
deﬁned by the EconLit database.
Despite important analytical differences and the lack of overlap between the body of literature addressed in our
analysis and Wagstaff and Culyer’s analysis of health economics within the EconLit database, our ﬁndings share
some commonalities. Both our analyses (along with Greenberg et al. (2010)) identiﬁed Harvard as the leading
institution and the USA as by far the most proliﬁc contributor to health economic (evaluation) research, followed
by the UK, and then the Netherlands, Canada, and Australia. China and South Africa also rank highly in both our
analyses. Nonetheless, our ﬁndings also differ in important ways. As expected, our lists of leading journals share
very little in common, as economic evaluations are predominantly published in biomedical journals, which are
not indexed in EconLit. Some contributors, such as the World Bank and Taiwan, which ranked very highly in
Wagstaff and Culyer’s analysis, contribute far less to economic evaluations, while institutions with a stronger
focus on health (rather than only economics) tend to rank more highly in our analysis. There are also substantial
differences with respect to our estimates of the volume of research. Whereas Wagstaff and Culyer ﬁnd that
‘economic evaluation . . .[shows] no clear trend’, our analysis has highlighted the substantial size of the applied
health economic evaluation literature relative to the health economics literature within EconLit and indicates
that with just 1% of the applied economic evaluation literature, the EconLit database is unlikely to provide a
representative indication of trends over time in the size or relative importance of health economic evaluation.
As previously highlighted (Wagstaff and Culyer, 2012), identifying health economic literature in the
biomedical databases was not straightforward. We found the use of economic vocabulary and article classiﬁca-
tions in biomedical journals and databases to be so poor and inconsistent as to render simultaneously sensitive
and speciﬁc searching impossible (Text S1). The NHS EED database, while incomplete, was by far the most
sensitive and speciﬁc source of economic evaluations, which makes the decision to cease to update it from
March 2015 particularly lamentable. The ongoing work to add DALY-based cost-utility analyses to the existing
QALY-based Tufts Economic Evaluation Registry is a welcome development; however, it will still omit half of
economic evaluations conducted in LMICs and currently charges for access.
Our ﬁndings paint a picture of a research community that is simultaneously highly concentrated in a few
countries and institutions and highly fragmented. A very small number of journals publish economic
evaluations from both high-income and low-income settings and a large proportion of articles appear in
journals which only very rarely publish economic evaluations. The fact that so many biomedical journals
now publish economic evaluations (if only rarely) is a positive sign of the acceptance and integration of
economic evaluation within health research. It is also perhaps unsurprising, as economic evaluations are usually
oriented towards health sector decision makers. This fragmentation may, however, also explain some of the
problems of quality highlighted elsewhere (Grifﬁths et al., 2016), as biomedical journal editors may not only
lack specialist knowledge of economic evaluation methods but also lack familiarity with pools of suitably
qualiﬁed reviewers. In this way, the small number of journals publishing economic evaluations about LMICs
may present an opportunity to engage with the editors of these journals to help improve standards where
necessary, whereas the vast array of authors, institutions, and journals associated with economic evaluations
set in HICs presents a greater challenge. In any case, the lack of scholarly dialogue between those focusing
on countries of differing income levels seems likely to be detrimental to all.
We hope that recognition of the size, importance, and fundamental interdisciplinarity of health economic
evaluation will lead to an evolution in research culture within the ﬁeld, and also, on a practical level, to
improvements in existing databases or creation of a new one that will better reﬂect and serve the needs of health
economics researchers. Of course, authors themselves, reviewers, and editors could already do far more to
facilitate the efﬁcient identiﬁcation of health economic evaluations. For example, an initial step could include
ensuring that all articles include the study design in their title, as is already required by Plos Medicine, and that
those that are not economic evaluations avoid economic terminology, such as ‘cost-effective’ in their titles,
abstracts, and keywords.
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4.2. Research priority setting
Our ﬁndings also raise a number of questions about the health and geographical areas that are and are not prioritised
for health economic evaluation. Burden of disease is not and should not be the sole determinant of the volume of
economic evaluation research. It seems difﬁcult to argue, however, that the differences between the number of
economic evaluations conducted across LICs, MICs, and HICs are equitable or efﬁcient. HICs account for 16%
of the world’s population, 11% of the GBD (WHO, 2014), and 83% of all economic evaluations conducted, while
LICs account for 12% of the world’s population, 19% of the GBD, and 4% of economic evaluations. There are 139
different LMICs (World Bank, 2015), which have very diverse epidemiological and economic characteristics, and
also, in many cases, weak(er) health systems with substantial and diverse constraints on the supply and demand for
health care; this diversity likely contributes to greater heterogeneity in the cost-effectiveness of interventions and
necessitates more, not less, research (Vassall et al., 2016). Further, the health beneﬁts foregone by incorrect priority
setting decisions may be substantially higher in low-income settings than in high-income settings.
One of our most surprising ﬁndings is how well the health areas studied in HICs correlate with the burden of
disease in those settings. In LMICs, however, the picture is much more mixed, with many more economic eval-
uations conducted about health areas accounting for lower proportions of the burden of disease. There are sev-
eral reasons why such discrepancies may not be inequitable or inefﬁcient. First, the GBD estimates themselves
are highly contested (Nord, 2013, Byass et al., 2013); intended to reﬂect only a very narrow deﬁnition of health,
the newest disability weights used in the GBD estimates exclude wider individual or social welfare conse-
quences (Salomon et al., 2012). In the case of HIV/AIDS, for example, the many and varied stakeholders could
therefore conclude that it is right that HIV should be studied more than health areas accounting for a larger bur-
den of disease because of its wider social and economic consequences or because its health consequences are
only lower than other diseases because of ongoing and expensive control efforts. Second, some health areas
may have a low value of additional information relative to the costs of generating the information, especially
if extensive research has already been conducted in that area. Third, so little may be understood about some
health problems at a clinical level that economic evaluation of interventions may be premature. Fourth, eco-
nomic evaluations may be conducted not to consider adding another more effective and more costly interven-
tion, but rather to consider divestment from costly interventions, and therefore economic evaluations in health
areas that contribute very little to the disease burden may be warranted. Finally, as economic evaluations are
conceptualised around a (package of) interventions, which may not map neatly onto speciﬁc conditions, cate-
gorization of economic evaluations by health areas also has some conceptual limitations, which could weaken
their correlation with disease burden; we found this to be particularly true for surgical procedures, pain manage-
ment and palliative care, and health systems and intersectoral interventions.
On the other hand, the four health areas accounting for the largest burden of disease in LICs are as follows:
(i) neonatal and maternal conditions; (ii) respiratory diseases; (iii) wounds and injuries; and (iv) diarrhoeal
diseases. While further biomedical advances, such as a point-of-care test for bacterial infections would help
(Zumla et al., 2014), the bulk of the impact of all four of these health areas needs to be addressed through health
systems, multi-sectoral, and/or social interventions such as prompt access to high-quality health facilities (Kerber
et al., 2007), road safety measures (WHO, 2013), and improved water and sanitation (Bartram et al., 2005). Such
solutions offer little potential for pharmaceutical company proﬁts and instead require complex interventions. Re-
cent systematic reviews of economic evaluations of cardiovascular disease interventions in LMICs similarly found
that evaluations of pharmacological interventions dominated and a greater focus on evaluation of non-clinical
strategies were needed (Shrouﬁ et al., 2013, Suhrcke et al., 2012). Financing such evaluations is unlikely to appeal
to private for-proﬁt companies, and so domestic and international research funders, as well as researchers them-
selves, should concentrate on producing research in these areas, and thereby correct this market failure.
4.3. Capacity development
Several of our ﬁndings have important implications for thinking about how to increase capacity to produce and
to use high-quality and policy-relevant health economic evaluations. Large upper-MICs, especially China but
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also South Africa, Brazil, and Iran, produce substantial numbers of economic evaluations and far more than
many smaller HICs. This is in some ways unsurprising, as the costs of research are independent of the size of
a country’s population or economy and so the relative costs of research are lower in large economies. Capacity
development is important for all countries, but particularly challenging for LMICs and for small HICs as well
(Kaló et al., 2016). A large gap between the numbers of economic evaluations conducted and what is needed
for priority setting persists in all but a few countries (Geroy, 2012, Odame, 2013, Mori and Robberstad, 2012).
Our analysis has identiﬁed some clear institutional leaders in LMICs, but also highlighted that many
countries produce few, if any, economic evaluations. We propose the development of strong regional or
sub-regional networks, which bring together existing capacity in health economic evaluation and build on
centres of strength in health intervention research, even where substantial economic evaluation capacity
may not yet exist. A multi-stakeholder report on how to strengthen health economics more generally
in Africa highlighted the importance of international networks as well as local institutional support
(McIntyre et al., 2008). In addition to training and ongoing technical support, a well-funded regional
network could also offer scope for deeper collaboration in producing multi-country evaluations and assessing
transferability of ﬁndings across the region. Such a regional approach could be more efﬁcient in generating
economic evidence and assessing its relevance to a wider range of settings more systematically.
The leading contributors to economic evaluations from LICs and lower-MICs tend to be research
institutions, often within or associated with ministries of health, rather than universities. Such embeddedness
should be an advantage in ensuring that research both reﬂects and informs a country’s health priorities. It also
means, however, that there may be no pre-existing link between those who conduct health economic evaluation
research and those who teach and train undergraduate and postgraduate students in these countries. This
marked difference from HICs and even upper-MICs may require new approaches to capacity development,
rather than replication of strategies that have achieved successes in upper-MICs and HICs.
At the same time, further work is needed to generate demand for economic evaluation both at national level,
through the institutionalization of priority setting (Odame, 2013, Mori and Robberstad, 2012), and globally,
through transparent priority-setting initiatives at global funding bodies and continuing efforts to strengthen
the role of economic evaluation in policy making at the WHO (Wiseman et al., 2016), whose policy recommen-
dations play a particularly large role in LICs and lower-MICs (WHO, 2012).
Finally, nearly half of economic evaluations studying LICs and lower-MICs do not include any authors from
LMIC institutions. Some of these were desk-based modelling studies; however, many involved data collection
in LMICs. Some may have included authors from LMICs afﬁliated with a HIC institution, for example as
doctoral students; however, such cases cannot explain the full magnitude of the discrepancy. It is unclear
whether this discrepancy reﬂects a lack of opportunities for participation from fellow researchers or funders,
lack of skills or incentives, or some combination of these and other factors, but the results are clearly inequi-
table (Chu et al., 2014). The situation also suggests a failure to recognise the wider potential of research
capacity development to improve health in LMICs and the more immediate impact that real partnership with
LMIC researchers and policy makers can have in ensuring that the research is policy-relevant and informs
policy decisions. Both funders and researchers in all countries must examine and address these inequities.
We hope that the ﬁndings of this analysis will be useful for those conducting (systematic) reviews of the
economic evaluation literature and that they will encourage and provide an empirical grounding for debate
on the current state and future directions for this growing ﬁeld.
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